Company Name
LAMINAR PHARMACEUTICALS
Activity
Transformation of medicine therapies developing innovative and pioneering drugs.
CIF
B57451171
Sector
BioPharmaceuticals
Address
Ctra. de Valldemossa Km. 7,4. ParcBIT. Edificio 17. 2º C-8 - Palma de Mallorca
EPM Joining Date
04/06/2020
Creation Date
17/10/2006
Founders Pablo V. Escribá, Vicenç Tur
Auditor
KPMG
Investors email contact
info@laminarpharma.com
Presenting Partner
Fellow Funders
Company profile
Continuous investment in Drug research and development (R&D) with high quality standards.
On the Road to BME Growth
- 23/07/2020 - Registered Advisor
- 29/09/2020 - Transformation in PLC
Relevant data
| (thousand of Euros) | 2020 | 2021 | 2022* | 2023* |
|---|---|---|---|---|
| Net worth | 10.995,77 | 14.875 | 28.524 | 54.458 |
| Net business turnover | 144,86 | 5.228 | 11.622 | 48.774 |
| Financial debt | 5.444,83 | 4.966 | 9.428 | 18.883 |
| Ebitda | -865,47 | 212 | -236 | 26.589 |
| Net Profit | -1.448,75 | 198 | -934 | 27.369 |
| Average number of employees | 19 | 21 | 25 | 30 |
| * Proyection | ||||
Investment Rounds
| Date | Status | Amount | Minimum Ticket |
|---|---|---|---|
| 11-10-2021 | Closed | 1.200.000 | 758,00 |
| 02-05-2022 | Closed | 20.000.000 | 947,50 |
| 15-11-2022 | Open | 17.999.998 | 25000,00 |
Business Model
License and supply to Big pharmas worldwide, under a B2B exploitation model
Competitive advantage
Development of oncological drugs as a new-generation of “First in class medicines” based on the innovative technology called MLT (Membrane lipid therapy), strongly patented worldwide. Our therapeutic platform uses highly safe therapeutic lipid molecules to improve the quality of life of people affected by some incurable diseases.
Scalability
Medicines innovation in the best interest of mankind
